header
Image from OpenLibrary

A pharmaceutical study on certain poorly soluble antihypertensive drug / Asmaa Abdelaziz Mohamed Bayoumi ; Supervised Mohamed Aly Kassem , Magdi Ibrahim Mohamed

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Asmaa Abdelaziz Mohamed Bayoumi , 2017Description: 265 P. : charts ; 25cmOther title:
  • دراسة صيدلية على شحيح الذوبان معين خافض لضغط الدم [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics Summary: Azilsartan kamedoxomil is a selective angiotensin II receptor antagonist, type1 (AT1) competi-tive antagonist. The US Food and Drug Administration (FDA) has approved Edarbi tablet (Azilsartan Medoxomil Potassium) on February 25, 2011, to treat hypertension in adults. It is available in 80 mg and 40 mg dosages. Many patients may prefer the oral route of administration to the more invasive other treatment options that includes injections especially if the oral formula could achieve a rapid onset of action. Azilsartan kamedoxomil is a poorly water soluble belongs to Biopharmaceutical Classification System (BCS class IV). One of the major problems of this drug is low solubility in biological flu-ids, which results in poor bioavailability after oral administration. Hence, its solubility should be enhanced to increase its bioavailability. In this work, azilsartan kamedoxomil was formulated in the form of rapidly dissolving stable tablets using different technique.
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.08.08.Ph.D.2017.As.P (Browse shelf(Opens below)) Not for loan 01010110073021000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.08.08.Ph.D.2017.As.P (Browse shelf(Opens below)) 73021.CD Not for loan 01020110073021000

Thesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics

Azilsartan kamedoxomil is a selective angiotensin II receptor antagonist, type1 (AT1) competi-tive antagonist. The US Food and Drug Administration (FDA) has approved Edarbi tablet (Azilsartan Medoxomil Potassium) on February 25, 2011, to treat hypertension in adults. It is available in 80 mg and 40 mg dosages. Many patients may prefer the oral route of administration to the more invasive other treatment options that includes injections especially if the oral formula could achieve a rapid onset of action. Azilsartan kamedoxomil is a poorly water soluble belongs to Biopharmaceutical Classification System (BCS class IV). One of the major problems of this drug is low solubility in biological flu-ids, which results in poor bioavailability after oral administration. Hence, its solubility should be enhanced to increase its bioavailability. In this work, azilsartan kamedoxomil was formulated in the form of rapidly dissolving stable tablets using different technique.

Issued also as CD

There are no comments on this title.

to post a comment.